A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Part of paid clinical trials in Springdale, Arkansas.

Sponsor
Bristol-Myers Squibb
Study ID
NCT03400332
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986253 — DRUG
    Specified dose on specified days
  • Nivolumab — BIOLOGICAL
    Specified dose on specified days
  • Ipilimumab — BIOLOGICAL
    Specified dose on specified days
  • Placebo — OTHER
    Specified dose on specified days

Study Details

The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.

Key Dates

Start date
Feb 12, 2018
Status verified
Jan 2026
Primary completion
Apr 26, 2024
Completion
Dec 4, 2025

Study Design

Enrollment
281 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1A: BMS-986253 + nivolumab
  • Experimental: Part 1B: BMS-986253 + nivolumab
  • Experimental: Part 1C: BMS-986253 + nivolumab + ipilimumab
  • Experimental: Part 2A: BMS-986253 + nivolumab + ipilimumab
  • Placebo Comparator: Part 2B: Placebo + nivolumab + ipilimumab

Primary Outcome Measure

Number of Participants Experiencing Adverse Events (AEs) - Part 1 [ Time Frame: From first dose up to 100 days after last dose (up to 65 months) ]

Locations (29)

FacilityCityStateZIPSite coordinators
Local Institution - 0059SpringdaleArkansas72762-
Local Institution - 0099Los AngelesCalifornia90033-
Local Institution - 0007LakewoodColorado80228-
Local Institution - 0087AtlantaGeorgia30322-
Local Institution - 0100AtlantaGeorgia30342-
Local Institution - 0101MariettaGeorgia30060-
Local Institution - 0012ColumbiaMaryland21044-
Local Institution - 0003LuthervilleMaryland21093-
Local Institution - 0060BostonMassachusetts02215-
Local Institution - 0004Ann ArborMichigan48109-
Local Institution - 0076OmahaNebraska68130-
Comprehensive Cancer Centers Of NevadaLas VegasNevada89169-
Local Institution - 0005HackensackNew Jersey07601-
Local Institution - 0032New BrunswickNew Jersey08903-
Local Institution - 0002New YorkNew York10032-
Local Institution - 0025New YorkNew York10029-
Local Institution - 0028Oklahoma CityOklahoma73104-
Local Institution - 0017EugeneOregon97401-
Local Institution - 0001PittsburghPennsylvania15213-
Local Institution - 0009GreenvilleSouth Carolina29615-
Local Institution - 0011AustinTexas78705-
Local Institution - 0010DallasTexas75246-
Local Institution - 0014Fort WorthTexas76104-3927-
Local Institution - 0018HoustonTexas77030-
Local Institution - 0006San AntonioTexas78240-
Local Institution - 0013TylerTexas75702-
Local Institution - 0058Salt Lake CityUtah84112-
Local Institution - 0015FairfaxVirginia22031-
Local Institution - 0008NorfolkVirginia23502-

Related coverage on Hipa.ai

Find similar trials in Springdale, AR

By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
Local Institution - 0059· Springdale, ARLocal Institution - 0099· Los Angeles, CALocal Institution - 0007· Lakewood, COLocal Institution - 0087· Atlanta, GALocal Institution - 0100· Atlanta, GALocal Institution - 0101· Marietta, GA

Related Studies